Research Paper Volume 15, Issue 24 pp 15228—15242

Figure 6. Summary of the study. (A) Summary of the mechanisms of action of lipid-lowering pharmaceutical agents included in our study. (B) Heatmap visualization of the Beta or OR estimates of lipid-lowering drug targets on different outcomes. The figure displays a matrix with rows representing gene targets of lipid-lowering agents and columns representing outcomes from different GWAS consortiums. The values in each square indicate the Beta or OR estimates and are color-coded based on their specific values. (B) Heatmap applied the gradually deepening orange, indicating the increasing Beta values. (C) Heatmap applied the deepening red indicating the increasing OR values and the deepening green representing the decreasing ORs. Abbreviations: TL, telomere length; CHD, Major coronary heart disease; CAS, Coronary atherosclerosis; T2D, Type 2 diabetes; HTN, hypertension; NAFLD, non-alcoholic fatty liver disease; OS, osteoporosis; CRC, colorectal cancer; GC, gastric cancer; EC, esophageal cancer; HCC, hepatocellular carcinoma; LC, lung cancer; PC, pancreatic cancer; TC, thyroid cancer, BC, bladder cancer; BT, brain tumors; COPD, chronic obstructive pulmonary disease; AD, Alzheimer's disease/dementia, OS, osteoporosis.